Klinisk cancergenomik – Johan Lindbergs forskargrupp

Min forskargrupp fokuserar på att upptäcka biomarkörer och utveckling av analys och informatik med ett särskilt intresse för blodbaserade biopsier. Teamet ansvarar för genomisk analys i prospektiva forskningsprojekt och randomiserade studier.

En del av:
Dekorativ bild

Vår forskning

Cancer Genomics-teamet har etablerat ett prov- och analysförfarande vid KI/SciLife som används vid biomarkördrivna randomiserade kliniska prövningar och prospektiva forskningsprojekt. Vi tar emot och lagrar biomaterial samt förbereder för Illumina-sekvensering och analys med hjälp av en egenutvecklad pipeline för bioinformatik och tillhörande programvara. Vi samarbetar med KI biobank och Clinical Genomics vid SciLife lab. Sedan 2016 har över 5500 prover från >50 hospitals i 6 europeiska länder analyserats och rapporterats.

Våra studier är främst ALASCCA och ProBio. De första resultaten från ProBio-studien har publicerats i Nature Medicine och nyligen publicerade vi resultat från ALASCCA-studien i ASCO-GI.

Läs gärna mer om vårt arbete med precisionsmedicinsk analys för prostatacancer och äggstockscancer.
Mer information om vår forskargrupp finns på den engelska sidan.

Publikationer

Alla gruppmedlemmars publikationer

Finansiering

Forskningsbidrag

  • Swedish Cancer Society
    1 January 2024
    This project was started to develop precision medicine for disseminated prostate cancer. All healthy individuals have DNA from dead cells in their blood. In patients with cancer, some of the free-floating DNA in blood comes from the cancer cells. This DNA is called circulating tumor DNA. In this project, new technology will be used to explore different uses for circulating tumor DNA, for example whether it can be used to follow treatment response and determine treatment choices. The project will study disseminated prostate cancer and all treatments used to treat this disease. The project is about using newly developed technology to identify biomarkers through analysis of circulating tumor DNA. The goal of this project is to provide oncologists with a tool to better follow and understand whether a patient is responding or not responding to a treatment by monitoring ctDNA levels in blood over time. Another goal is to improve treatment choices through analysis of circulating tumor DNA.
  • Swedish Cancer Society
    1 January 2021
    Prostate cancer is the most common form of cancer in Sweden. Although survival is 92% after 5 years, prostate cancer takes the most lives of all cancer types. A challenge with prostate cancer is that many men carry a completely harmless cancer that will not cause any symptoms if left undetected. The widespread PSA testing therefore leads to unnecessary side effects and costs to society. The Stockholm3 test is a blood test based on a combination of biomarkers that was developed to meet these challenges. Combined with new technology that improves the precision of biopsy, the problems have decreased but there is room for improvement. To reduce the problems in screening for prostate cancer, new types of biomarkers are needed. One such biomarker is DNA remnants from dying cancer cells which can be purified and analyzed from plasma. Such DNA residues are called circulating tumor DNA. In this research project, circulating tumor DNA will be analyzed from patients diagnosed with prostate cancer as well as healthy individuals to investigate whether circulating tumor DNA has the potential to identify those men who need treatment and those who should not. The goal of this research is to develop a diagnostic test to improve screening for prostate cancer.

Medarbetare och kontakt

Gruppledare

Alla medarbetare i gruppen

Besöksadress

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Nobels väg 12A, Stockholm, 171 77, Sweden

Postadress

Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, PO Box 281, Stockholm, 171 77, Sweden

Nyckelord:
Bioinformatik (beräkningsbiologi) (Tillämpningar under 10610) Biomarkörer Cancer och onkologi Flytande biopsi Genomik Visa alla
Innehållsgranskare:
Johan Lindberg
Gunilla Sonnebring
2025-09-04